Dogwood Therapeutics (DWTX) director awarded 16,800 options at $1.50 strike price
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Dogwood Therapeutics director David R. Keefer received a new stock option grant for 16,800 shares of common stock. The options have an exercise price of $1.50 per share, allowing him to buy shares at that price in the future. Following this grant, he holds 16,800 options directly. The options become exercisable starting June 16, 2027 and expire on June 16, 2036, making this a long-term, compensation-related award rather than an open-market trade.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Keefer David R
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 16,800 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 16,800 shares (Direct, null)
Footnotes (1)
Key Figures
Option grant size: 16,800 shares
Exercise price: $1.50 per share
Total options after grant: 16,800 options
+2 more
5 metrics
Option grant size
16,800 shares
Stock Option (right to buy) grant to director Keefer
Exercise price
$1.50 per share
Conversion or exercise price of the stock option
Total options after grant
16,800 options
Total derivative shares following transaction, direct ownership
Exercise start date
June 16, 2027
Option exercise date
Expiration date
June 16, 2036
Option expiration date
Key Terms
Stock Option (right to buy), exercise price, grant/award acquisition, expiration date
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 1.5000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
grant/award acquisition financial
"transaction_action: grant/award acquisition"
expiration date financial
"expiration_date: 2036-06-16T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Dogwood Therapeutics (DWTX) director David R. Keefer report on this Form 4?
David R. Keefer reported receiving a stock option grant for 16,800 shares of Dogwood Therapeutics common stock. This is a compensation-related award, not an open-market trade, and gives him the right to buy shares at a fixed exercise price.
How many Dogwood Therapeutics (DWTX) options were granted to David R. Keefer?
He was granted stock options covering 16,800 shares of Dogwood Therapeutics common stock. These options increase his potential equity exposure and represent his total reported derivative holdings following the transaction, according to the Form 4 data provided.
What is the exercise price of David R. Keefer’s Dogwood Therapeutics (DWTX) options?
The stock options have an exercise price of $1.50 per share. This means he can purchase Dogwood Therapeutics common stock at $1.50 per share once the options become exercisable, regardless of the market price at that time.
When can David R. Keefer exercise his Dogwood Therapeutics (DWTX) stock options?
The options become exercisable on June 16, 2027. From that date until their expiration, he can choose to exercise them and buy Dogwood Therapeutics common stock at the fixed $1.50 per-share exercise price.
When do David R. Keefer’s Dogwood Therapeutics (DWTX) options expire?
The stock options expire on June 16, 2036. After that expiration date, any unexercised portion of the 16,800-share grant will lapse, and he will no longer have the right to purchase those shares at $1.50.
Is this Dogwood Therapeutics (DWTX) Form 4 a buy or sell transaction in the market?
This Form 4 reports a grant of stock options, not a market buy or sell. It is classified as a grant or award acquisition, providing compensation through options rather than reflecting an open-market stock purchase or sale.